BioStock: Cereno Scientific enters collaboration with Abbott

Swedish biopharma company Cereno Scientific has taken yet another important step towards initiating a phase II clinical trial with lead programme CS1 by entering into a collaboration agreement with global healthcare company Abbott. The agreement stipulates that Cereno Scientific will use Abbott’s CardioMEMS HF System in the upcoming phase II trial to remotely and continuously monitor the pulmonary pressure in pulmonary arterial hypertension patients being treated with CS1.

Read the article at biostock.se:

https://www.biostock.se/en/cereno-scientific-enters-collaboration-with-abbott/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se